Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025)
Invivyd's (IVVD) quarterly Non-Current Deferred Tax Liability came in at $719000.0 in Q4 2025, down 99.22% YoY from $92.0 million in Q4 2024, and down 99.22% on a QoQ basis from $92.0 million in Q4 2024.
Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025) Analysis & Trends
Invivyd (IVVD) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $719000.0 in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 99.22% year-over-year to $719000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $719000.0 (down 99.22% YoY) and the FY2025 annual result came in at $719000.0, down 99.22% from the prior year.
- Non-Current Deferred Tax Liability declined to $719000.0 in Q4 2025, from $92.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $92.0 million in Q4 2024 to a low of $719000.0 in Q4 2025.
- A 3-year average of $55.6 million and a median of $74.1 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability gained 24.07% — and 2025, when it sank 99.22%.
- Tracing IVVD's Non-Current Deferred Tax Liability over 3 years: stood at $74.1 million in 2023, then climbed by 24.07% to $92.0 million in 2024, then slumped by 99.22% to $719000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $719000.0 (Q4 2025), $92.0 million (Q4 2024), and $74.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 719,000.00 |
| Dec 31, 2025 | 719,000.00 |
| Dec 31, 2024 | 91.95 Mn |
| Dec 31, 2024 | 91.95 Mn |
| Dec 31, 2023 | 74.12 Mn |
| Dec 31, 2023 | 74.12 Mn |